Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Deferred Revenue (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Deferred Revenue for 14 consecutive years, with $58000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 61.11% to $58000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $58000.0, a 61.11% increase, with the full-year FY2024 number at $61000.0, up 56.41% from a year prior.
  • Current Deferred Revenue was $58000.0 for Q3 2025 at Gyre Therapeutics, up from $28000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.0 million in Q2 2021 to a low of $28000.0 in Q1 2025.
  • A 5-year average of $409333.3 and a median of $59500.0 in 2024 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 517.58% in 2021; the steepest drop was 88.4% in 2021.
  • Gyre Therapeutics' Current Deferred Revenue stood at $230000.0 in 2021, then crashed by 36.96% to $145000.0 in 2022, then tumbled by 73.1% to $39000.0 in 2023, then surged by 56.41% to $61000.0 in 2024, then decreased by 4.92% to $58000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Current Deferred Revenue are $58000.0 (Q3 2025), $28000.0 (Q1 2025), and $61000.0 (Q4 2024).